Skip to Content
Merck
CN
All Photos(1)

Documents

676492

Sigma-Aldrich

MAZ51

≥95% (HPLC), solid, VEGFR3 kinase inhibitor, Calbiochem®

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
VEGFR3 Kinase Inhibitor, MAZ51, MAZ51, 3-(4-Dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one, Vascular Endothelial Growth Factor Receptor 3 Kinase Inhibitor, VEGFR Tyrosine Kinase Inhibitor XVI, VEGFR3 Kinase Inhibitor I
Empirical Formula (Hill Notation):
C21H18N2O
CAS Number:
163655-37-6
Molecular Weight:
314.38
UNSPSC Code:
12352200
NACRES:
NA.77

product name

VEGFR3 Kinase Inhibitor, MAZ51, The VEGFR3 Kinase Inhibitor, MAZ51, also referenced under CAS 163655-37-6, controls the biological activity of VEGFR3 Kinase. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

Quality Level

100

Assay

≥95% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
protect from light

color

red

solubility

DMSO: 10 mg/mL

shipped in

ambient

storage temp.

2-8°C

InChI

1S/C21H18N2O/c1-23(2)20-12-11-14(15-7-3-4-9-17(15)20)13-18-16-8-5-6-10-19(16)22-21(18)24/h3-13H,1-2H3,(H,22,24)

InChI key

VFCXONOPGCDDBQ-UHFFFAOYSA-N

General description

A cell-permeable 3-substituted indolin-2-one compound that acts as a reversible and ATP-competitive VEGF receptor tyrosine kinase inhibitor. At low concentration (≤5 µM), it specifically blocks VEGF-C- (Cat. No. 676476) and VEGF-D- (Cat. No. 676471) induced phosphorylation of VEGFR-3, but not VEGFR-2, in PAE cells. It partially blocks VEGFR-2 phosphorylation only at higher concentrations (50 µM). This differential blocker may be useful for inhibiting lymphangiogenesis-dependent pathological process such as tumor metastasis. Not available for sale in Germany.
A cell-permeable, 3-substituted, indolin-2-one compound that acts as a reversible and ATP-competitive inhibitor of VEGF receptor tyrosine kinase. At low concentrations (5 µM), reported to specifically block VEGF-C and VEGF-D-induced phosphorylation of VEGFR-3, but not VEGFR-2, in PAE cells. Reported to partially block VEGFR-2 phosphorylation only at higher concentrations (50 µM). This differential inhibition may be useful for controlling lymphangiogenesis-dependent tumor metastasis and could, therefore, be of clinical significance for cancer therapy studies.

Biochem/physiol Actions

Cell permeable: yes
Primary Target
VEGF receptor tyrosine kinase
Product competes with ATP.
Reversible: yes
Target IC50: At low concentration (≤5 µM), it specifically blocks VEGF-C- and VEGF-D-induced phosphorylation of VEGFR-3, but not VEGFR-2, in PAE cells.

Packaging

Packaged under inert gas

Warning

Toxicity: Standard Handling (A)

Other Notes

Kirkin, V., et al. 2001. Eur. J. Biochem.268, 5530

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

WGK

WGK 3

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Pu-Hong Zhang et al.
JCI insight, 9(1) (2023-11-17)
The lymphatic vasculature is the natural pathway for the resolution of inflammation, yet the role of pulmonary lymphatic drainage function in sepsis-induced acute respiratory distress syndrome (ARDS) remains poorly characterized. In this study, indocyanine green-near infrared lymphatic living imaging was
Jinman Chen et al.
Nature communications, 11(1), 3159-3159 (2020-06-24)
Extravasated erythrocytes in cerebrospinal fluid (CSF) critically contribute to the pathogenesis of subarachnoid hemorrhage (SAH). Meningeal lymphatics have been reported to drain macromolecules and immune cells from CSF into cervical lymph nodes (CLNs). However, whether meningeal lymphatics are involved in
Raj Kumar et al.
Cell death & disease, 11(5), 325-325 (2020-05-10)
Pathological retinal neovascularization is the most common cause of vision loss. PKCθ has been shown to play a role in type 2 diabetes, which is linked to retinal neovascularization. Based on these clues, we have studied the role of PKCθ

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service